PharmacyCodes



Lopirin [Switzerland] en es it fr

Categoria

Lopirin [Switzerland] Marchi, Lopirin [Switzerland] Analoghi

Lopirin [Switzerland] Marchi miscela

  • No information avaliable

    • Lopirin [Switzerland] Formula chimica

    C9H15NO3S

    Lopirin [Switzerland] RX link

    http://www.rxlist.com/cgi/generic/captop.htm

    Lopirin [Switzerland] FDA foglio

    Lopirin [Switzerland] DMS (foglio di materiale di sicurezza)

    Lopirin_[Switzerland] MSDS

    Lopirin [Switzerland] Sintesi di riferimento

    DW Cushman, US Pat. 4,046,889 (1977)

    Lopirin [Switzerland] Peso molecolare

    217.286 g/mol

    Lopirin [Switzerland] Temperatura di fusione

    106oC

    Lopirin [Switzerland] H2O Solubilita

    Solubile

    Lopirin [Switzerland] Stato

    Solid

    Lopirin [Switzerland] LogP

    0.546

    Lopirin [Switzerland] Forme di dosaggio

    Compressa (12,5 mg, 25 mg, 50 mg o 100 mg)

    Lopirin [Switzerland] Indicazione

    Per il trattamento dell'ipertensione. Può essere usato da solo o in combinazione con diuretici tiazidici.

    Lopirin [Switzerland] Farmacologia

    Captopril, un inibitore dell'enzima di conversione dell'angiotensina (ACE), è usato per trattare l'ipertensione, insufficienza cardiaca congestizia, e sindromi renali come la nefropatia diabetica e la sclerodermia. Gli effetti negativi e limitazioni di farmacocinetica di captopril stimolato l'enalapril e il successivo sviluppo ACE-inibitori.

    Lopirin [Switzerland] Assorbimento

    75% senza cibo (la presenza di cibo nel tratto gastrointestinale riduce l'assorbimento di circa il 30 al 40 per cento).

    Lopirin [Switzerland] Tossicita

    Sintomi di sovradosaggio comprendono coma, letargia, ipotensione, lentezza, e lo stomaco e irritazione intestinale e iperattività.

    Lopirin [Switzerland] Informazioni paziente

    Patients should be advised to immediately report to their physician any signs or symptoms suggesting angioedema (e.g., swelling of face, eyes, lips, tongue, larynx and extremities; difficulty in swallowing or breathing; hoarseness) and to discontinue therapy.

    Patients should be told to report promptly any indication of infection (e.g., sore throat, fever),which may be a sign of neutropenia, or of progressive edema which might be related to proteinuria and nephrotic syndrome.

    All patients should be cautioned that excessive perspiration and dehydration may lead to an excessive fall in blood pressure because of reduction in fluid volume. Other causes of volume depletion such as vomiting or diarrhea may also lead to a fall in blood pressure; patients should be advised to consult with the physician.

    Patients should be advised not to use potassium-sparing diuret-ics, potassium supplements or potassium-containing salt substitutes without consulting their physician.

    Patients should be warned against interruption or discontinuation of medication unless instructed by the physician.

    Heart failure patients on captopril therapy should be cautioned against rapid increases in physical activity.

    Patients should be informed that captopril should be taken one hour before meals.

    Lopirin [Switzerland] Atto interessato organismi

    Gli esseri umani e altri mammiferi